Trending...
- NIUFO Examines European MiCA Regulation's Impact on Digital Asset Trading Markets
- AHRFD Releases Market Analysis: Cryptocurrency Market's Institutional Transformation Accelerating
- Ubleu Crypto Group Analyzes European Digital Asset Market Opportunities Amid Regulatory Evolution
SEATTLE, April 9, 2021 /PRNewswire/ -- Today, FidaLab, a CLIA-certified clinical diagnostic company based in Seattle announced its partnership with Concentric by Ginkgo to provide a scalable and simple testing modality - pooled testing - to serve K-12 schools.
As more and more schools work to support in-person learning environments, communities across the country have turned to COVID-19 testing to monitor the virus. Even as teachers and guardians become eligible for vaccines, clinical vaccine trials for individuals under 16 are just beginning, and efforts to track and mitigate viral spread remain critical.
Concentric by Ginkgo's goal is to provide easy, affordable pooled testing to every school in America. Pooled classroom testing, which combines swabs from all consenting individuals in a classroom and runs them as a single test can significantly increase testing capacity and lower the cost of testing programs. Over 800 hundred schools are currently signed up to test with Concentric across the country.
"We are excited at the prospect of joining Ginkgo to provide mass COVID testing in schools to help maintain in-person learning environments in Washington. Ginkgo has proven itself in successfully implementing school testing programs in the State of Massachusetts, Maryland, and beyond. The combination of our local testing capability and Ginkgo's experience and organizational strength will provide a very reliable option for Washington school systems," said Myles Yu, Chief Medical Officer of FidaLab.
More on Washingtoner
On February 17, 2021, the U.S. Department of Health and Human Services (HHS) in partner with the Department of Defense (DOD) has announced a $650 million investment to expand COVID-19 testing capacity for K-8 schools to support President Biden's plan to re-open schools for in-person learning.
"The funding provided by the Biden Administration will help make it possible for schools in Washington and across the country to engage in pooled testing for every student, every week," said Jason Kelly, CEO and co-founder of Ginkgo Bioworks. "Testing in schools will support the entire community by providing opportunities to limit the spread, and to interrupt chains of transmission."
FidaLab joined the fight against the COVID-19 pandemic at the very beginning and has built massive PCR testing capability for SARS-CoV-2, the virus that causes COVID-19. FidaLab has provided mass testing in collaboration with large scale county testing, schools, long term care facilities, athletic teams and more.
To learn more about Concentric by Ginkgo or to get your school district involved, head over to concentricbyginkgo.com.
About FidaLab
FidaLab is a privately owned CLIA-certified clinical laboratory based in Seattle with a specialty in molecular diagnosis of infectious diseases using cutting edge biotechnologies. With its proven diagnostic accuracy and 24-hour turnaround time, FidaLab has earned the trust of the communities it serves.
More on Washingtoner
About Ginkgo Bioworks
Concentric by Ginkgo is Ginkgo Bioworks' public health and biosecurity effort. Headquartered in Boston, Ginkgo uses the most advanced technology on the planet—biology—to grow better products. The company's cell programming platform is enabling the growth of biotechnology across diverse markets, from food to fragrance to pharmaceuticals. Ginkgo is also actively supporting a number of COVID-19 response efforts, including community testing, epidemiological tracing, vaccine development and therapeutics discovery. For more information, visit www.ginkgobioworks.com.
Ginkgo Bioworks Contact:
[email protected]
FidaLab Contact:
[email protected]
Related Images
image1.jpg
SOURCE FidaLab LLC
As more and more schools work to support in-person learning environments, communities across the country have turned to COVID-19 testing to monitor the virus. Even as teachers and guardians become eligible for vaccines, clinical vaccine trials for individuals under 16 are just beginning, and efforts to track and mitigate viral spread remain critical.
Concentric by Ginkgo's goal is to provide easy, affordable pooled testing to every school in America. Pooled classroom testing, which combines swabs from all consenting individuals in a classroom and runs them as a single test can significantly increase testing capacity and lower the cost of testing programs. Over 800 hundred schools are currently signed up to test with Concentric across the country.
"We are excited at the prospect of joining Ginkgo to provide mass COVID testing in schools to help maintain in-person learning environments in Washington. Ginkgo has proven itself in successfully implementing school testing programs in the State of Massachusetts, Maryland, and beyond. The combination of our local testing capability and Ginkgo's experience and organizational strength will provide a very reliable option for Washington school systems," said Myles Yu, Chief Medical Officer of FidaLab.
More on Washingtoner
- Spokane: 1914 "Golden Spike" Marker Placed Monday, September 15
- Spokane: Construction Project Changes
- Spokane City Council to Consider Day Change of Legislative Sessions
- Your Body Isn't Broken—It's Out of Balance: The New Book Revealing the Blueprint to Restore Hormone Balance, Sleep, Gut & Metabolic Health
- Spokane: Funding Available for Tourism and Cultural Investment Grants
On February 17, 2021, the U.S. Department of Health and Human Services (HHS) in partner with the Department of Defense (DOD) has announced a $650 million investment to expand COVID-19 testing capacity for K-8 schools to support President Biden's plan to re-open schools for in-person learning.
"The funding provided by the Biden Administration will help make it possible for schools in Washington and across the country to engage in pooled testing for every student, every week," said Jason Kelly, CEO and co-founder of Ginkgo Bioworks. "Testing in schools will support the entire community by providing opportunities to limit the spread, and to interrupt chains of transmission."
FidaLab joined the fight against the COVID-19 pandemic at the very beginning and has built massive PCR testing capability for SARS-CoV-2, the virus that causes COVID-19. FidaLab has provided mass testing in collaboration with large scale county testing, schools, long term care facilities, athletic teams and more.
To learn more about Concentric by Ginkgo or to get your school district involved, head over to concentricbyginkgo.com.
About FidaLab
FidaLab is a privately owned CLIA-certified clinical laboratory based in Seattle with a specialty in molecular diagnosis of infectious diseases using cutting edge biotechnologies. With its proven diagnostic accuracy and 24-hour turnaround time, FidaLab has earned the trust of the communities it serves.
More on Washingtoner
- Youth Take the Lead: Kopp Foundation for Diabetes Hosts "By Youth, For Youth, With T1D" Gala on October 8 at Blue Bell Country Club
- Green Office Partner Named #1 Best Place to Work in Chicago by Crain's for 2025
- CCHR, a Mental Health Watchdog Organization, Hosts Weekly Events Educating Citizens on Important Mental Health Issues
- "Leading From Day One: The Essential Guide for New Supervisors" Draws from 25+ Years of International Management Experience
- REI's Member Days bring 11 days of exclusive offers and expanded benefits to get outside
About Ginkgo Bioworks
Concentric by Ginkgo is Ginkgo Bioworks' public health and biosecurity effort. Headquartered in Boston, Ginkgo uses the most advanced technology on the planet—biology—to grow better products. The company's cell programming platform is enabling the growth of biotechnology across diverse markets, from food to fragrance to pharmaceuticals. Ginkgo is also actively supporting a number of COVID-19 response efforts, including community testing, epidemiological tracing, vaccine development and therapeutics discovery. For more information, visit www.ginkgobioworks.com.
Ginkgo Bioworks Contact:
[email protected]
FidaLab Contact:
[email protected]
Related Images
image1.jpg
SOURCE FidaLab LLC
Filed Under: Business
0 Comments
Latest on Washingtoner
- Apellix Deploys Breakthrough Spray-Painting Drones into Live Service Limited Beta Program Open for Advanced Contractors
- DivX Unveils New Educational Blog Series to Simplify MKV to MP4 Video Conversion
- SKYLAR DIGGINS ADVANCES TO PLAYOFFS AFTER WEARING 422 GRAMS OF PROTEIN--MADE WITH MILK
- CCHR: For Prevention, Families Deserve Truth From NIH Study on Psychiatric Drugs
- Sheets.Market Brings Professional Financial Model Templates to Entrepreneurs and Startups
- Webinar Announcement: Investing in the European Defense Sector—How the New Era of Uncertainty Is Redefining Investment Strategies
- AEVIGRA (AEIA) Analysis Reveals $350 Billion Counterfeit Market Driving Luxury Sector Toward Blockchain Authentication
- Tacoma: City Council Unanimously Approves Funding for Immigrant Detainee Support
- City Council Approves Lateral Incentive Program for Tacoma Police Department
- Spokane: SPD Asking for Help Identifying Suspects in an Arson
- Her Magic Mushroom Memoir Launches as a Binge-Worthy Novel-to-Podcast Experience
- Tacoma: 2025 AMOCAT Arts Award Winners Announced
- Trade Tech Strengthens International Presence Across Four New Markets
- Century Fasteners de Mexico Hires Saúl Pedraza Gómez as Regional Sales Manager in Mexico
- Tacoma: Nominations Open for Dr. Martin Luther King, Jr. Community Service Awards
- Georgia Misses the Mark Again on Sports Betting, While Offshore Sites Cash In
- $40 Price Target for $NRXP in H. C. Wainright Analyst Report on Leader in $3 Billion Suicidal Depression Market with Superior NRX 100 Drug Therapy
- Nashville International Chopin Piano Competition Partners with Crimson Global Academy to Support Excellence in Education
- AHRFD Releases Market Analysis: Cryptocurrency Market's Institutional Transformation Accelerating
- Ubleu Crypto Group Analyzes European Digital Asset Market Opportunities Amid Regulatory Evolution